SCHEMBL273580

SCHEMBL273580

[CH2]NCC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534488 0.87
SCHEMBL396976 0.84
SCHEMBL1488097 0.80
SCHEMBL1488424 0.76 NCF1 (0.50)
SCHEMBL6353032 0.70
SCHEMBL1007436 0.69
SCHEMBL18225062 0.67
Hydrochloric Acid SCHEMBL5395215 0.67 SAT1 (0.46)
SCHEMBL18774035 0.65
SCHEMBL16870313 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10556908-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-02-11 US claimed
US-20190106426-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2019-04-11 US claimed
US-10112950-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2018-10-30 US claimed
US-20170369497-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2017-12-28 US claimed
US-9695180-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2017-07-04 US claimed
US-20160009720-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2016-01-14 US claimed
US-8344018-B2 Oxindolyl inhibitor compounds GILEAD SCIENCES, INC. (US) 2013-01-01 US claimed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 US claimed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 US claimed
US-8134000-B2 Imidazolyl pyrimidine inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-03-13 US claimed
WO-2006040526-A1 QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER ASTRAZENECA AB (SE) 2006-04-20 WO claimed
WO-2006041888-A2 SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 2006-04-20 WO claimed
EP-1633743-A1 CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ Amgen, Inc. (US) 2006-03-15 EP claimed
EP-1631542-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF Amgen, Inc. (US) 2006-03-08 EP claimed
US-20050234044-A1 Cyclic amine derivatives and methods of use AMGEN INC. 2005-10-20 US claimed
WO-2005061467-A2 PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS AMGEN INC. (US) 2005-07-07 WO claimed
US-20050124654-A1 Compounds and methods of use AMGEN INC. 2005-06-09 US claimed
US-20050014749-A1 analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects AMGEN INC. 2005-01-20 US claimed
WO-2004092116-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF AMGEN, INC. (US) 2004-10-28 WO claimed
WO-2004092164-A1 CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ AMGEN, INC. (US) 2004-10-28 WO claimed